#ESMO21 Highlights on pembro + chemo in 1st-line metastatic cervical cancer: The KEYNOTE-826 study

#ESMO21 Highlights on combination of pembrolizumab plus chemotherapy in mTNBC: The KEYNOTE-355 studyПодробнее

KEYNOTE-826: pembrolizumab + chemotherapy vs placebo + chemotherapy for cervical cancerПодробнее

KEYNOTE-826: Pembrolizumab plus chemotherapy for patients with metastatic cervical cancerПодробнее

ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 studyПодробнее

#ESMO21 Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 studyПодробнее

#ESMO21 Highlights on nivo+ipi vs EXTREME in 1st-line high-risk SCCHN: The CheckMate 651 studyПодробнее

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancerПодробнее

KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancerПодробнее

#ESMO21 Highlights on atezolizumab combined with FOLFOXIRI + bev in 1st-line mCRC: AtezoTRIBE studyПодробнее

#ESMO21 Highlights on aspirin use in recurrent platinum-resistent ovarian cancer: EORTC-1508 studyПодробнее

#ESMO21 Highlights on patterns of relapse in NSCLC to atezolizumab vs BSC after adj CT: IMpower010Подробнее

Gynecologic Oncology at ASCO 2022: Subgroup Analysis of KEYNOTE-826Подробнее

#ESMO21 Highlights on maintenance olaparib in ovarian cancer previously treated with PARPiПодробнее

Pembrolizumab With Chemotherapy as First Line for Metastatic Cervical CancerПодробнее

#ESMO21 Expert Video Report on head and neck cancerПодробнее

#ESMO22 Highlights on pembrolizumab with CRT in locally advanced HNSCC: The KEYNOTE-412 studyПодробнее

Gynecologic Oncology at ESMO Congress 2021: Trial Study in Cervical CancerПодробнее

#ESMO21 Highlights on a phase I of dual RAF/MEK inhibitor + FAK inhibitor in ovarian cancer (FRAME)Подробнее

#ESMO21 Highlights on adagrasib in patients with KRASG12C-mutated CRC: The KRYSTAL-1 studyПодробнее